Tumor mutation burden and FAT3 mutation influence long-term survival in surgically resected small cell lung cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High tumor mutation burden (TMB) and FAT3 mutations may predict long-term survival in small cell lung cancer (SCLC) patients after surgery. This finding could help identify patients likely to achieve better outcomes following SCLC resection.
Area Of Science
- Oncology
- Genomics
- Cancer Research
Background
- Small cell lung cancer (SCLC) is aggressive with high recurrence rates post-surgery.
- Identifying factors for long-term survival (LTS) in SCLC patients remains a challenge.
- Understanding molecular differences between long-term and short-term survivors is crucial.
Purpose Of The Study
- To investigate the genetic characteristics associated with long-term survival (LTS) in surgically resected SCLC.
- To compare genomic profiles and tumor mutation burden (TMB) between LTS and short-term survival (STS) SCLC patient groups.
Main Methods
- Comparative genomic profiling and TMB analysis of tumor tissues from 11 SCLC patients (6 LTS, 5 STS).
- Next-generation sequencing was used to assess genomic profiles and calculate TMB.
- Molecular characteristics were analyzed and compared between LTS and STS groups.
Main Results
- Tumor tissues from LTS patients exhibited significantly higher TMB (median ~16.4 mutations/Mb) compared to STS patients (median ~8.5 mutations/Mb).
- The FAT3 mutation was exclusively identified in the long-term survival group.
- A trend towards significant difference in TMB was observed between LTS and STS groups (P=0.08).
Conclusions
- High non-synonymous TMB and FAT3 mutations may be potential indicators of long-term survival post-SCLC resection.
- This study highlights key molecular distinctions between SCLC patients with differing survival outcomes.
- Larger studies are warranted to validate these preliminary findings.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...